Senseonics Holdings, Inc. (NYSE American: SENS) experienced a sharp 11.52% decline in its stock price during Tuesday's trading session, following the company's announcement of preliminary third-quarter results and plans for a reverse stock split. The medical technology firm, known for its implantable continuous glucose monitoring systems, faced a negative market reaction despite reporting significant revenue growth.

According to the company's preliminary unaudited results, Senseonics generated approximately $8.1 million in revenue for the third quarter of 2025, marking a 91% increase compared to the same period last year. This growth was primarily driven by a 160% surge in new patient starts in the U.S. market. Despite exceeding analysts' expectations of $7.8 million in revenue, investors appeared to focus on other aspects of the announcement.

The market's adverse response seems to be largely influenced by Senseonics' decision to implement a 1-for-20 reverse stock split, scheduled to take effect on October 17, 2025. This move will reduce the number of outstanding common shares from about 816 million to approximately 41 million. While reverse stock splits are often implemented to maintain compliance with stock exchange listing requirements or to attract institutional investors, they can sometimes be perceived negatively by the market. The combination of these announcements, despite the company's growth in revenue and patient numbers, appears to have triggered a significant sell-off, reflecting investor uncertainty about Senseonics' future prospects and financial stability.